Lead Product(s) : SC0062
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BioCity’s SC0062 Meets Phase 2 Primary Endpoint in Diabetic Kidney Disease
Details : SC0062 is one of the most unique, oral endothelin A (ETA)-receptor selective antagonist, small molecule drug. It is being evaluated for the treatment of diabetic kidney disease.
Product Name : SC0062
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 25, 2025
Lead Product(s) : SC0062
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SC0062
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BioCity’s SC0062 Receives Breakthrough Therapy For IgA Nephropathy
Details : SC0062 is one of the most unique, oral endothelin A (ETA)-receptor selective antagonist, small molecule drug. It is being evaluated for the treatment of IgA Nephropathy.
Product Name : SC0062
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 26, 2024
Lead Product(s) : SC0062
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SC0062
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BioCity’s SC0062 Meets Primary Endpoint in IgA Nephropathy in 2-SUCCEED Phase 2 Trial
Details : SC0062 is one of the most unique, oral endothelin A (ETA)-receptor selective antagonist, small molecule drug. It is being evaluated for the treatment of IgA Nephropathy.
Product Name : SC0062
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 07, 2024
Lead Product(s) : SC0062
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SC0062
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BioCity Completes Enrollment in Phase II Trial of SC0062 for IgA Nephropathy
Details : SC0062 is one of the most unique, oral endothelin A (ETA)-receptor selective antagonist, small molecule drug. It is being evaluated for the treatment of IgA Nephropathy.
Product Name : SC0062
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 26, 2024
Lead Product(s) : SC0062
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SC0062
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SC0062 is designed with high selectivity for ETA receptors antagonists, which is investigated for the treatment of chronic kidney disease with albuminuria.
Product Name : SC0062
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 21, 2023
Lead Product(s) : SC0062
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Solnatide
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Quan Capital
Deal Size : $60.0 million
Deal Type : Series B Financing
Alebund Pharmaceuticals Raises $60 million in Series B Financing Round
Details : Alebund Pharmaceuticals lead product, AP-301, is a best-in-class potential in the treatment of hyperphosphatemia.
Product Name : AP-301
Product Type : Peptide
Upfront Cash : Undisclosed
September 05, 2021
Lead Product(s) : Solnatide
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Quan Capital
Deal Size : $60.0 million
Deal Type : Series B Financing